🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for ALK Positive

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC NCT05498064n/a1 site📍 Beijing Peking Union Medical College Hospital · Tests: Ensartinib DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers NCT05770037Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Alectinib A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL) NCT07001384Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Alectinib, Duvelisib A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib NCT06378892Phase 29 sites📍 Aviano📍 Florence📍 Lido di Camaiore Centro di Riferimento Oncologico - Aviano · Tests: Lorlatinib Gilteritinib for the Treatment of ALK NSCLC NCT06225427Phase 13 sites📍 Los Angeles📍 Washington D.C.📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Gilteritinib Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer NCT05765877Phase 21 site📍 Jinan Pingping Song · Tests: WX-0593 Tablets Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context NCT06487078NA32 sites📍 Toulouse📍 Paris📍 Aix-en-Provence Pfizer · Tests: Lorlatinib Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC NCT06092086Phase 21 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: Loratinib Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690Phase 12 sites📍 Houston📍 Houston Baylor College of Medicine · Tests: C7R.CD30.CAR-EBVST cells Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC NCT06765109Phase 3159 sites📍 Glendale📍 Newport Beach📍 Orange Nuvalent Inc. · Tests: Neladalkib (NVL-655), Alectinib Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study NCT07696832n/a1 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: Ivonescimab Injection A Registry for People With T-cell Lymphoma NCT05978141n/a26 sites📍 Duarte📍 San Diego📍 San Francisco Memorial Sloan Kettering Cancer Center · Tests: Optional Blood Sample and Nail Sample Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors NCT04925609Phase 1, Phase 22 sites📍 Paris📍 Utrecht Princess Maxima Center for Pediatric Oncology · Tests: Brigatinib Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL NCT07013565Phase 21 site📍 Valhalla New York Medical College · Tests: Vinblastine (Velban), Brentuximab vedotin (Adcetris), Nivolumab (Opdivo) International Rare Histiocytic Disorders Registry (IRHDR) NCT02285582n/a15 sites📍 Birmingham📍 Los Angeles📍 Madera The Hospital for Sick Children · Tests: Registry study A Phase 1/2 Study of SY-12321 in Patients With ALK-positive Advanced Malignancies NCT07810933Phase 1, Phase 22 sites📍 Guangzhou📍 Nanjing Shouyao Holdings (Beijing) Co. LTD · Tests: SY-12321 Study of SGR-1505 in Mature B-Cell Neoplasms NCT05544019Phase 136 sites📍 Gilbert📍 Newark📍 Pompano Beach Schrödinger, Inc. · Tests: SGR-1505 Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT NCT05236946Phase 31 site📍 Mumbai Tata Memorial Hospital · Tests: Stereotactic radiosurgery/whole brain radiotherapy, Tyrosine kinase inhibitor Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma NCT07300514Phase 31 site📍 Shanghai Fudan University · Tests: PET-CTandct- DNAdetection, golidocitinib, Placebo Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer NCT05241028Phase 21 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: Ensartinib A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) NCT07140016Phase 117 sites📍 Fullerton📍 Orange📍 Edwards Astellas Pharma Global Development, Inc. · Tests: gilteritinib Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib NCT07374614n/a1 site📍 Shenzhen Peking University Shenzhen Hospital · Tests: Iruplinalkib tablets Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy NCT06862869n/a44 sites📍 Zhanjiang📍 Guangzhou📍 Kaifeng Hoffmann-La Roche · Tests: Alectinib Study of NXP900 With Lorlatinib in ALK+ Lung Cancer NCT07784959Phase 11 site📍 Fairfax Nuvectis Pharma, Inc. · Tests: NXP900, Lorlatinib Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer NCT07415005Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Lorlatinib A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC NCT07491497Phase 1, Phase 216 sites📍 San Francisco📍 Aurora📍 Boston TRIANA Biomedicines, Inc. · Tests: TRI-611 Alectinib Pharmacokinetic in Patients With NSCLC NCT05713006Phase 1, Phase 21 site📍 Mexico City Instituto Nacional de Cancerologia de Mexico · Tests: Alectinib Oral Product Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy NCT06834373Phase 27 sites📍 Scottsdale📍 Jacksonville📍 Albert Lea Mayo Clinic · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therapy, Computed … AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer NCT07617337Phase 17 sites📍 Houston📍 Nagoya📍 Kashiwa Chugai Pharmaceutical · Tests: AQUA07, Lorlatinib Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients NCT06361589n/a1 site📍 Chengdu Sichuan Cancer Hospital and Research Institute · Tests: Lorlatinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy